PMID- 25489725
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20210301
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 48
IP  - 4-5
DP  - 2015 Mar
TI  - PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial 
      infarction treated with heparin and PCI.
PG  - 322-8
LID - S0009-9120(14)00781-4 [pii]
LID - 10.1016/j.clinbiochem.2014.11.022 [doi]
AB  - OBJECTIVES: Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) 
      predict outcome in patients with acute coronary syndrome (ACS). Unfortunately, 
      administration of heparin to patients with ACS increases circulating PAPP-A, 
      probably by a detachment of PAPP-A from cell surfaces, inducing a considerable 
      bias when using PAPP-A as a biomarker. It remains unknown whether PAPP-A-derived 
      N- and C-terminal fragments of insulin-like growth factor binding protein-4 
      (NT-IGFBP-4/CT-IGFBP-4) are acutely affected by the increase in PAPP-A. METHODS: 
      We prospectively included 78 patients with ST-segment elevation myocardial 
      infarction (STEMI) treated with percutaneous coronary intervention (PCI). Prior 
      to PCI, patients were injected with 10,000IU of unfractionated heparin (UFH). 
      Blood samples were collected immediately before PCI, but after UFH-injection, 
      immediately after PCI and on day 1 and day 2. Plasma IGFBP-4, CT-IGFBP-4 and 
      NT-IGFBP-4 levels were determined by specific, novel immunoassays, and PAPP-A and 
      IGF-I by commercial immunoassays. RESULTS: Plasma PAPP-A was strongly elevated 
      upon STEMI, UFH-administration and PCI with mean concentrations (95%-confidence 
      interval) pre-PCI, post-PCI, day 1, and day 2 of 13.0 (11.2;15.2), 14.8 
      (13.1;16.8), 1.03 (0.90;1.18), and 1.08 (0.92;1.28) mug/L, respectively 
      (p<0.0001). Pre-PCI concentrations of IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 were 154 
      (142;166), 53 (47;60) and 136 (122;150) mug/L, and levels were unaltered post-PCI. 
      Concentrations increased on day 1 by 63 (43;87)%, 69 (36;110)%, and 47 (21;79)%, 
      respectively (p<0.0001), i.e. at a time point when PAPP-A levels had normalized. 
      CONCLUSION: Plasma IGFBP-4-fragment levels are not acutely altered in patients 
      with STEMI treated with UFH and PCI. Thus, they possess potentials as prognostic 
      markers in ACS patients.
CI  - Copyright (c) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier 
      Inc. All rights reserved.
FAU - Hjortebjerg, Rikke
AU  - Hjortebjerg R
AD  - Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, 
      Aarhus University, Aarhus, Denmark; The Danish Diabetes Academy, Odense, Denmark. 
      Electronic address: rikke.hjortebjerg@clin.au.dk.
FAU - Lindberg, Soren
AU  - Lindberg S
AD  - Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark.
FAU - Hoffmann, Soren
AU  - Hoffmann S
AD  - Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark.
FAU - Jensen, Jan S
AU  - Jensen JS
AD  - Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark; 
      Institute of Clinical Medicine, Faculty of Health Sciences, University of 
      Copenhagen, Copenhagen, Denmark.
FAU - Oxvig, Claus
AU  - Oxvig C
AD  - Department of Molecular Biology and Genetics, Faculty of Science and Technology, 
      Aarhus University, Aarhus, Denmark.
FAU - Bjerre, Mette
AU  - Bjerre M
AD  - Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, 
      Aarhus University, Aarhus, Denmark.
FAU - Frystyk, Jan
AU  - Frystyk J
AD  - Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, 
      Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal 
      Medicine, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141206
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 4)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.24.- (Pregnancy-Associated Plasma Protein-A)
RN  - EC 3.4.24.79 (PAPPA protein, human)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Biomarkers/blood
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 4/*blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/diagnosis/*therapy
MH  - *Percutaneous Coronary Intervention/trends
MH  - Pregnancy-Associated Plasma Protein-A/*metabolism
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute coronary syndrome (ACS)
OT  - Biomarker
OT  - Cardiovascular disease
OT  - Heparin
OT  - IGF binding protein-4 (IGFBP-4)
OT  - IGFBP-4 fragment
OT  - Insulin-like growth factor (IGF)
OT  - Pregnancy-associated plasma protein-A (PAPP-A)
OT  - ST-segment elevation myocardial infarction (STEMI)
EDAT- 2014/12/10 06:00
MHDA- 2016/01/05 06:00
CRDT- 2014/12/10 06:00
PHST- 2014/08/22 00:00 [received]
PHST- 2014/11/04 00:00 [revised]
PHST- 2014/11/27 00:00 [accepted]
PHST- 2014/12/10 06:00 [entrez]
PHST- 2014/12/10 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - S0009-9120(14)00781-4 [pii]
AID - 10.1016/j.clinbiochem.2014.11.022 [doi]
PST - ppublish
SO  - Clin Biochem. 2015 Mar;48(4-5):322-8. doi: 10.1016/j.clinbiochem.2014.11.022. 
      Epub 2014 Dec 6.